These new findings have led investigators to search for molecular changes within dysregulated FTE that may accompany tumor development in patients and animal models, including FTE‐derived genetically engineered mouse models (GEMMs) targeting three key HGSC genetic alterations as shown by The Cancer Genome Atlas (TCGA) and previous studies5: Brca1/2(+/- or ‐/‐); Tp53(R172H/‐); and Pten(‐/‐) via a conditional Pax8‐Cre doxycycline‐inducible system.6 Here, PTEN is linked to neoplasm.